Novartis agreed to acquire Pikavation Therapeutics, Synnovation’s subsidiary, for up to $3 billion including $2 billion upfront to secure SNV4818, a pan‑mutant selective PI3Kα inhibitor in early clinical testing for HR+/HER2‑ metastatic breast cancer. Novartis said SNV4818 targets mutated PI3Kα while sparing wild‑type enzyme to improve tolerability and enable combinations with endocrine therapies. Synnovation will retain other R&D units and continue independent programs. Mutant‑selective PI3Kα inhibitors aim to limit on‑target toxicities that have hindered earlier compounds.